BIOASTER announces a collaboration with LNC Therapeutics, a leading biotech in the development of innovative microbiome-based therapies, located in Bordeaux, France. The aim of the partnership is to support LNC Therapeutics’ R&D activities. It will rely on BIOASTER’s expertise and proprietary ANOXIC platform to isolate and cultivate new strains of the strictly anaerobic bacterial species Christensenella from complex human samples.
Find out more about the BIOASTER ANOXIC platform
watch the video dedicated: https://youtu.be/VaD6XuviD8E
Find out more about LNC Therapeutics